Influence of hypertonic-hyperoncotic solution and furosemide on canine hydrostatic pulmonary oedema resorption.
1. This study aimed at enhancing the clearance of experimental hydrostatic pulmonary oedema in dogs using hypertonic-hyperoncotic solution (HHS) and furosemide. 2. Anaesthetized dogs (n = 20) were mechanically ventilated with a positive end-expiratory pressure of 10 cmH2O (1.0 kPa). 3. Hydrostatic pulmonary oedema was induced by inflating a balloon inserted into the left atrium and simultaneously infusing isotonic saline rapidly. Oedema formation was terminated by deflating the balloon and reducing the infusion rate. 4. Four groups were studied: A, control; B, furosemide; C, HHS and D, HHS+furosemide. HHS, 6 ml kg-1, was given as a bolus injection and furosemide, 1 mg kg-1, intravenously as a bolus followed by an infusion of 0.5 mg kg-1 h-1. All dogs were studied for 4 h. 5. Serum osmolarity, plasma colloid oncotic pressure and diuresis in groups C and D (HHS groups) substantially increased; haemoglobin concentration decreased and pulmonary arterial wedge pressure remained constant. 6. Despite the combination of these factors favouring fluid flux from the extravascular to the intravascular compartment, extravascular lung water measured with the double indicator dilution technique decreased no faster in the HHS groups than in the two other groups (from over 26 to approximately 19 ml kg-1 in groups A, C and D and to 14.7 in group B (only furosemide)). 7. This was confirmed by postmortem gravimetric measurements of extravascular lung water; A, 11.0 +/- 5.7; B, 9.7 +/- 3.3; C, 10.5 +/- 3.1 and D, 10.6 +/- 1.8 g kg-1. 8. We speculate that mechanisms other than effective Starling gradients and enhanced diuresis might define a maximal rate of pulmonary oedema clearance.
Wickerts
C J
CJ
Institution of Clinical Physiology, University Hospital of Uppsala, Sweden.
Berg
B
B
Frostell
C
C
Schmidt
J
J
Blomqvist
H
H
Rösblad
P G
PG
Kihlström
I
I
Messmer
K
K
Hedenstierna
G
G
D000818:Animals; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D015633:Extravascular Lung Water / Q000378:metabolism; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006982:Hypertonic Solutions; D008297:Male; D009994:Osmolar Concentration; D009997:Osmotic Pressure; D011654:Pulmonary Edema / Q000188:drug therapy* / Q000378:metabolism
D006982:Hypertonic Solutions; D005665:Furosemide